<DOC>
	<DOCNO>NCT00092027</DOCNO>
	<brief_summary>This study ass safety tolerability MK0217 evaluate treat woman postmenopausal osteoporosis .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability MK0217 Women ( 0217-219 )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Women postmenopausal osteoporosis High risk fracture Esophageal abnormality Upper gastrointestinal symptom relieve medication Metabolic bone disease ( example vitamin D deficiency ) Medications would affect breakdown buildup bone</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>